Rectal Cancer-Pipeline Review, H1 2016

Rectal Cancer-Pipeline Review, H1 2016

  • Products Id :- GMDHC7771IDB
  • |
  • Pages: 112
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


Global Markets Direct's, 'Rectal Cancer-Pipeline Review, H1 2016', provides an overview of the Rectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Rectal Cancer

The report reviews pipeline therapeutics for Rectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rectal Cancer therapeutics and enlists all their major and minor projects

The report assesses Rectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rectal Cancer

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rectal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rectal Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Rectal Cancer-Overview 7

Rectal Cancer-Therapeutics under Development by Companies 8

Rectal Cancer-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Rectal Cancer-Products under Development by Companies 11

Rectal Cancer-Companies Involved in Therapeutics Development 12

AbbVie Inc. 12

Advaxis, Inc. 13

Cerulean Pharma, Inc. 14

Hanwha Chemical Corporation 15

Karyopharm Therapeutics, Inc. 16

Regeneron Pharmaceuticals, Inc. 17

Synta Pharmaceuticals Corp. 18

Taiwan Liposome Company, Ltd. 19

Rectal Cancer-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

axalimogene filolisbac-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

CB-24-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CRLX-101-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ganetespib-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

HD-204-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

nimotuzumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

selinexor-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

TLC-388-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

veliparib-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ziv-aflibercept (recombinant)-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Rectal Cancer-Recent Pipeline Updates 64

Rectal Cancer-Dormant Projects 108

Rectal Cancer-Product Development Milestones 109

Featured News & Press Releases 109

Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 109

Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 109

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Figures

Number of Products under Development for Rectal Cancer, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Assessment by Monotherapy Products, H1 2016 20

Number of Products by Top 10 Targets, H1 2016 21

Number of Products by Stage and Top 10 Targets, H1 2016 21

Number of Products by Top 10 Mechanism of Actions, H1 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23

Number of Products by Routes of Administration, H1 2016 25

Number of Products by Stage and Routes of Administration, H1 2016 25

Number of Products by Molecule Types, H1 2016 27

Number of Products by Stage and Molecule Types, H1 2016 27

List of Tables

Number of Products under Development for Rectal Cancer, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Comparative Analysis by Early Stage Development, H1 2016 10

Products under Development by Companies, H1 2016 11

Rectal Cancer-Pipeline by AbbVie Inc., H1 2016 12

Rectal Cancer-Pipeline by Advaxis, Inc., H1 2016 13

Rectal Cancer-Pipeline by Cerulean Pharma, Inc., H1 2016 14

Rectal Cancer-Pipeline by Hanwha Chemical Corporation, H1 2016 15

Rectal Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 16

Rectal Cancer-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 17

Rectal Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2016 18

Rectal Cancer-Pipeline by Taiwan Liposome Company, Ltd., H1 2016 19

Assessment by Monotherapy Products, H1 2016 20

Number of Products by Stage and Target, H1 2016 22

Number of Products by Stage and Mechanism of Action, H1 2016 24

Number of Products by Stage and Route of Administration, H1 2016 26

Number of Products by Stage and Molecule Type, H1 2016 28

Rectal Cancer Therapeutics-Recent Pipeline Updates, H1 2016 64

Rectal Cancer-Dormant Projects, H1 2016 108

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

AbbVie Inc.

Advaxis, Inc.

Cerulean Pharma, Inc.

Hanwha Chemical Corporation

Karyopharm Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Taiwan Liposome Company, Ltd.

Rectal Cancer Therapeutic Products under Development, Key Players in Rectal Cancer Therapeutics, Rectal Cancer Pipeline Overview, Rectal Cancer Pipeline, Rectal Cancer Pipeline Assessment

select a license
Single User License
USD 2000 INR 146940
Site License
USD 4000 INR 293880
Corporate User License
USD 6000 INR 440820



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]